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EXPLANATION OF THESIS FORMAT 
This thesis is divided into two sections, each of which is to be 
submitted for publication. The literature review is meant to provide a 
context for the research presented i.n Sections I and II. At the end of 
Sections I and II is a discussion of the results of the research 
presented in those sections. A summary of the research and conclusions 
drawn from the data generated by the research is provided at the 
conclusion of the text. 
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LITERATURE REVIEW 
Introduction 
Conditions in dogs and humans such as neoplasia and immune 
mediated illness are more common in older populations and occur, in 
part, through a failure of one or more components of the immune system 
(41,43,47,50). The decline of immune function and increased 
susceptibility to disease seem to be unavoidable consequences of aging 
(14,19,50,56). A reversal, however, of the aging associated decline of 
immune function could lead to a decrease in some "old age" illnesses 
attributable to illl'Tiune senescence. The objective of this study is to 
evaluate several non-toxic agents that when supplementing the daily 
ration of dog food will mitigate the increased susceptibility of 
different age populations of dogs to diseases linked to immune 
senescence. 
Neuroendocrine Influences on the Thymus Gland and Changes Associated 
with Aging 
The thymus gland has consistently been identified as an organ that 
has enormous control over the ontogeny and competence of the immune 
system (14,17,19,25,28). Thymic epithelial cells provide the 
microenvironment through which thymocytes migrate during their 
maturation and differentiation into T-lymphocytes (34). Under a light 
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microscope, the epithelial cells of the thymus are seen as an extensive 
network of cells with long projections of cytoplasm extending between 
thymocytes. The anatomy and fine structure of human and rodent thymus 
epithelial cells has recently been reviewed (33). 
Thymic epithelial cells produce hormone substances that control 
many processes related to the immune system (25,28,34). The best 
described of the many thymic hormones that participate in the 
development of T-lymphocytes are thymosin fraction 5, thymopoietin and 
thymulin (35). The structure and some of the functions of the various 
fractions have recently been reviewed by Incefy (28) and Goldstein et 
al. (25). Thymosin fraction 5 is an impure extract from bovine thymus 
glands. When added to bone marrow cells in vitro, it causes their 
differentiation into cells biochemically and functionally 
indistinguishable from T-lymphocytes (34). Thymopoietin is another 
extract from the bovine thymus. It exists in two forms, which differ 
by two amino acids. Thymopoietin induces expression of some T-
lymP,hocyte alloantigens in stem cells and stimulates many T-lymphocyte 
functions (41). Thymulin is a zinc containing serum thymic factor 
(also known as facteur thymique serique or FTS) that was first isolated 
from swine serum (41). Thymulin stimulates most T-lymphocyte functions 
(41). The function of 8-lymphocytes is not dependent upon the thymus 
although the function of B-lymphocytes is regulated by helper or, 
suppressor subsets of T-lymphocytes (47). 
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The thymus gland of humans and dogs normally begins a process of 
progressive age related involution and decline of thymic hormone 
secretion starting shortly after puberty (41,43,47-49). An age 
associated decline in the thymic dependent (cell-mediated) immune 
system begins at approximately the same point in life (50). Secretion 
of growth hormone (GH), a product of the adenohypophysis, also declines 
with age from peak secretion at puberty (14,42,53). The events of age 
related thymic involution and the decline in the thymus dependent 
immune system and the decline in GH secretion approximately parallel 
each other over time (24,45,47,56). It is becoming evident that these 
events are highly interrelated. 
When neonatal mice are surgically thymectomized they become 
immunoincompetent and they develop a wasting syndrome that is 
characterized by failure to grow, then weight loss and death (45). A 
similar clinical syndrome is seen when normal neonatal mice are 
innoculated with heterologous anti-mouse hypophysis or heterologous 
anti-bovine growth hormone immunoglobulin (45). In both instances the 
mice have inhibition of body growth, involution of the thymus gland, 
reduced or absent lymphocytes in the thymus dependent areas of the 
spleen, a diminished response to mitogens and a wasting syndrome that 
is similar to that observed after neonatal thymectomy (40,47). The 
actions of heterologous antisera in these experiments suggested an 
intimate relationship between GH which is secreted by the 
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adenohypophysis, the thymus, and immune competence. 
Other investigations with autosomal recessive Snell-Bagg pituitary 
dwarf mice have further characterized the relationship between the 
adenohypophysis and the thymus gland (pituitary-thymic axis) 
(17,18,55). These mice ·are almost totally GH deficient ·and they 
develop a severe immunodeficiency (hypoplasia of the thymus gland and 
peripheral lymphoid tissue, lymphopenia and failure to reject allogenic 
skin grafts) and a wasting syndrome similar to that observed in 
thymectomized neonatal mice (49). Treatment of these mice with bovine 
growth hormone (bGH) alone or in combination with Thyroxine (T4) 
restores the normal morphologic features of the thymus and the impaired 
immune function and prevents the fatal wasting syndrome (45). The 
enhanced effectiveness seen in several of the combined bGH and T4 
treatments is consistent with the concept that thyroid hormone 
functions in a "permissive" manner, sensitizing target tissue for 
increased responsiveness to other hormones (39). Normalization of 
immune function was not observed when dwarf mice were thymectomized as 
adults and treated with bGH. This suggests that the thymus and not bGH 
was responsible for the reconstitution of impaired cellular immunity 
(45). 
A series of experiments have further clarified certain aspects of 
the rodent pituitary-thymic axis (13,31,32). In one experiment, Kelly 
et al. found that is was possible to regenerate normal thymic structure 
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and T-cell function in 18 and 24 month old Wister-Furth rats that had 
been implanted with GH3 cells (pituitary adenoma cells that secete GH 
and prolactin) (13,32). The thymuses of the 18 month old GH3 implanted 
rats had distinct cortical thymocytes and medullary epithelial cells 
and were histologically indistinguishable from those of 3 month old 
controls (13,32). The responses of T-cells from the 18 month old GH3 
implanted rats to standard mitogens were 2 to 5 times higher than 
comparable control rats (32). The thymus glands of the 24 month old 
GH3 implanted rats had increased cellularity and fewer adipocytes than 
controls, but they were not fully reconstituted (32). Responses of T-
cells from the 24 month old GH3 implanted rats to standard mitogens and 
interleukin 2(IL-2) production were greatly enhanced when compared with 
controls ( 32) • 
In another experiment with 27 month old female Fischer 344 rats 
that were treated with GH, prolactin or GH plus prolactin, prolactin 
was found to augment the proliferative responses of splenocytes to 
standard mitogens (31). In contrast to the experiment with GH3 
implanted Wistar-Furth rats, exogenous GH did not affect the size or 
fat content of the thymus glands but GH did increase the numbers of 
epithelial cells and thymic corpuscles (31). Prolactin had no 
detectable effect on the thymus glands and neither hormone affected IL-
2 synthesis from mitogen activated splenocytes (31). 
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When Davila et al. gave ovine GH to 26 month old Fisher 344 rats 
for five weeks they found that mitogenic responses and natural killer 
(NK) activity of splenocytes were enhanced even though the morphology 
of their thymuses were unchanged (13). Enhanced thymic size is 
apparently not required for the reconstitutive effects of GH. 
Thymus glands from six week old transgenic mice (mice containing 
an exogenous metallothionein-rat GH gene that express high rat GH 
concentrations in serum) were found to have more epithelial cells and 
thymic corpuscles and less adipose tissue than thymus glands from 
normal littermates (13). Splenocyte proliferation at suboptimal 
mitogen concentrations were greater in transgenic than in control 
littermate mice, but neither IL-2 synthesis or antibody synthesis to 
sheep erythrocytes were affected (13). 
Davila et al. also implanted GH3 cells into Rowett nude 
(congenitally athymic) rats and responses to T-cell mitogens, IL-2 
synthesis, antibody synthesis to sheep erythrocytes, and NK activity 
were found to be unaffected which suggests that the thymus gland is the 
unifying link between GH and immune enhancement (13). 
Collectively, these experiments show that GH can regenerate the 
thymus glands of old rodents and that T-cells and NK cells from aged 
rats are not inherently defective because their mitogenic responses and 
cytolytic activity can be augmented by exogenous GH. Growth hormone 
can also augment T-cell proliferative responses in young rodents but 
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the immunoenhancing effects are not as apparent as those observed in 
immunocompromised aged animals (13). 
Bovine GH has been shown to be active in immunodeficient sex-
1 inked dwarf White Leghorn chickens. When 200 mg/kg of bGH was given 
subcutaneously to day old chicks once a day for 3 weeks it resulted in 
enhancement of the humoral immune system and bursal growth in a manner 
analogus to the thymotrophic and cell-mediated immune system 
enhancement seen in mammals (39). 
The effect of thymectomy on puppies is unclear and has recently 
been reviewed (49). In one study, dog fetuses thymectomized after 48 
days of gestation showed no evidence of a wasting syndrome, had normal 
lymphoid tissue development but defective humoral and cell-mediated 
immune response (14). Other studies of thymectomized puppies report 
normal humoral and cell-mediated immune response (normal allograft 
rejection) and no signs of a wasting syndrome (58). A different author 
reported that thymectomy of one month old puppies resulted in 
inappropriate survival of allo9rafts which indicates defective cell-
mediated immunity (54). Still another author reported that 18 of 18 
thymectomized puppies 3 to 6 weeks of age died of a wasting syndrome 
while only one of 9 puppies thymectomized between 10-12 weeks of age 
died of a wasting syndrome (55). Differences in surgical techniques 
(complete vs incomplete thymectomy), age at thymectomy, breed of dog, 
nutritional factors, and environmental infectious agents are likely 
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among the factors contributing to the conflicting reports on the effect 
of thymectomy in puppies (4g). 
Immunodeficient pituitary dwarf Weimaraner dogs also exhibit a 
lack of thymus cortex, growth hormone deficiency and a wasting syndrome 
similar to that of Snell-Bagg mice (47-49). When affected pups were 
treated with either thymosin fraction 5 (an impure thymic hormone 
containing many thymus derived peptides and polypeptides) or bGH, 
clinical improvement and a marked increase in the thickness and 
cellularity of the cortex of the thymus was observed (48,49). Improved 
mitogen responsiveness (cell-mediated immunity) in these dogs, however, 
was variable (49). 
When young (2-5 year old) adult dogs with the normal age related 
involution of the thymus were given bGH subcutaneously (0.1 mg/kg; 14 
doses in 30 days) they show more consistent regeneration of their 
thymus glands than did comparable controls who were given bovine serum 
albumin (BSA) (42). Mitogen responsiveness of lymphocytes from these 
dogs given bGH was quite variable but this variability was consistent 
with other reports of dogs similarily treated (49). 
Growth Hormone 
In the normal animal, GH is spontaneously and episodically 
secreted by cells of the adenohypophysis in response to a variety of 
stimuli (20). The actions of GH are mediated by at least two 
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somatomedins, A and C (20,44). 
Somatomedin A and C are peptides with molecular weights of 7500 
daltons. Because of their similarity to proinsulin, they are also 
known as proinsulin-like growth factors (IGF) I and II. Growth hormone 
stimulates the secretion of somatomedin C (IGF-I) by the liver. 
Somatomedin A (IGF-II) is only weakly GH dependent (20). 
The effects of GH on carbohydrate metabolism occur primarily via 
the promotion of hyperglycemia through insulin antagonism (20,23). 
Secondary hyperinsulinemia and diabetes mellitus may follow prolonged 
or sustained increases in plasma GH concentrations (20). 
The secretion of GH is regulated by endogenous neural rhythms 
(sleep rhythms, stress and exercise promote secretion), 
neurotransmitters (B-adrenergic inhibit while alpha-adrenergic and 
dopaminergic stimulate secretion) somatostatin (inhibits secretion) and 
hormonal feedback loops acting on the pituitary and hypothalamus 
(9,20,23,44). The majority of stimuli affect GH release by influencing 
hypothalamic secretion of growth hormone releasing hormone (GHRH) or 
somatostatin (7,9,20). However, the dominant influence of the 
hypothalamus on GH secretion is stimulatory (20). 
Variations exist between and among species in the secretion of GH 
in response to stimuli. For example, moderate exercise will stimulate 
GH release in humans (30) but not in dogs (20). Arginine is a potent 
stimulant to GH secretions in humans (2) and rats (11), but has given 
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inconsistent results in the dog (20). The GH response to insulin-
induced hypoglycemia in dogs has also been variable (20). In humans, 
several studies have shown a diminished response of GH secretion to 
clonidine in patients with depression or panic when compared with 
controls (15,56). 
Secretagogues of Growth Hormone 
A variety of agents including arginine (3), ornithine (16), L-dopa 
(17), insulin (37), glucose (20) and clonidine (46) have been used in 
humans and rodents to induce the secretion of GH under a variety of 
clinical and experimental conditions. 
Clonidine 
Clonidine is a specific vasomotor center alpha-2 adrenoceptor 
agonist that is inhibitory to sympathetic central nervous system (CNS) 
outflow activity (36). Clonidine has effects on the CNS similar to 
those of chlorpromazine. It produces a marked, but dose-dependent, 
sedation in humans and in laboratory animals (44). Its major clinical 
use in humans is in the treatment of essential hypertension 
(spontaneous elevation of blood pressure) and in the provocative 
testing of the status of endogenous GH secretion (27,30). 
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Intravenous or oral clonidine has been shown to be a safe and 
reliable test of GH secretion in normal children and adolescent and 
adult humans (8,27). Evidence of some neonatal and adult rat models 
indicate that clonidine stimulates GH secretions via stimulation of the 
hypothalamic neurons that synthesize or store GHRH (9,46). In children 
(4 to 12 years) however, clonidine induced GH secretion is not preceded 
by elevations in GHRH (7). Clonidine does not increase GH secretion in 
adult humans with essential hypertension or during exercise (8,30). 
Other studies indicate that GH release during periods of exercise 
following clonidine administration may be dependent upon endogenous 
opiate stimulation (23). The effects of clonidine on GH secretion are 
delayed in opiate addicted humans and blunted in depressed (15) or 
panicked humans (56) or when given with amphetamine (51). 
The use of clonidine in humans as a screening test for GH 
deficiency in short children is not universally accepted (37). A 
subset of short statured children (3.5 to 20.6 years) who had normal GH 
secretion after provocative testing but markedly reduced 24 hour 
endogenous GH output has been identified (6). In addition, marked 
variation in GH responsiveness of children (3 to 13 years) have been 
reported after oral clonidine (37). 
Clonidine has effects on other endocrine hormones besides GH 
(8,35,46). The effects of clonidine on plasma cortisol are 
inconsistent and vary with the test population (35;27). Oral clonidine 
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in some studies is reported to depress plasma cortisol concentrations 
by 50% from 90 to 120 minutes after a single dose of clonidine in 
normal and in GH deficient children and in healthy adults (8). The 
decreased cortisol values are accompanied by a 50% drop in plasma ACTH 
concentrations. Other authors have reported no difference in plasma 
cortisol concentration following clonidine administration (46). In a 
different study of GH response during exercise, clonidine blunted 
plasma catecholamine increase by more than 60% of the control responses 
without significant.ly altering the normal exercise induced rise of 
plasma cortisol or ACTH (30). 
In opiate addicted adult humans, clonidine did not induced the 50% 
decrease of plasma cortisol concentrations that was observed in non-
addicted controls (22). Clonidine was also found to raise the opiate 
depressed plasma B-endorphin concentrations in addicted humans and it 
was capable of blocking acute opiate withdrawal symptoms (22). 
Clonidine had no effect on the plasma B-endorphin concentrations of 
non-opiate addicted controls (22). 
Clonidine is reported to have no effect on plasma concentrations 
of follicle-stimulating hormone, thyrotropin, glucose, lutenizing 
hormone, prolactin, testosterone or estradiol B-17 (8,35,36,46). 
Arginine 
Arginine is an amino acid that is essential for dogs during growth 
and during adult life (38). All tissues utilize arginine for 
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cytoplasmic and nuclear protein biosynthesis (2). Intestinal 
absorption of arginine occurs via a.transport system shared with 
lysine, ornithine and cystine (2). Since arginine is a constituent of 
the urea cycle, dietary deficiency suppresses hepatic conversion of 
ammonia to urea and symptoms of hepatoencephalopathy can develop (2). 
Dietary arginine deficiency has lead to cataract formation in dog and 
wolf pups raised on commercially available milk replacer (38). 
Old Balb/c mice given dietary supplementation with arginine had 
recovery of age related decline of mitogen responsiveness and 
expression of T-cell markers (19). Endocrine activity of the thymus in 
these mice, as measured by thymulin production, was also reactivated. 
When arginine was combined with lysine the beneficial effects on thymic 
and immune function were further enhanced (19). 
Supplemental dietary arginine has been demonstrated to promote 
wound healing, improve thymic weight and size and· to abrogate post-
traumatic weight loss and immune suppression in rats (3,4,5). 
Supplemental dietary arginine will also increase thymic weights in 
uninjured rats and it can lessen or abrogate the thymolytic effects of 
stress (2). 
The exact mechanism of arginines thymotrophism is unkwown but it 
appears to require an intact hypothalamic-hypophyseal axis (2). None 
of the beneficial effects of supplemental dietary arginine of enhanced 
wound healing and restoration of thymic and immune function are 
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observed in hypophysectomized rats or in hypophysectomized rats given 
bGH (2). In other experiments with hypophysectomized rats supplemented 
with saline, thyroxine, and testosterone, arginine failed to improve 
wound healing (2). 
Arginine is considered safe in normally nourished animals (2). In 
rats the LD50 (intraperitoneal, after a 24 hour fast) for arginine is 
3.8 g/kg (2). Humans can tolerate intravenous doses of 0.5 g/kg up to 
30 g total over 20-30 minutes without side effects (2). Only a single 
case of anaphylaxis to arginine infusion has been reported (2). 
Caution is urged in the use of arginine in humans with severe metabolic 
alkalosis, renal insufficiency, and hepatic insufficiency (2). 
Recently, arginine infusions have been shown to lead to 
hypophosphatemia in normal and insulin-dependent human diabetics (2). 
The hypophosphatemic effect of arginine may be due to displacement of 
intracellular potassium by the cationic amino acid arginine (2). 
Arginine, when perfused through isolated canine pancreas glands, 
·stimulates both glucagon and insulin secretion which are also highly 
influenced by the glucose concentration of the perfusion medium (29). 
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Ornithine 
Ornithine is a non-essential amino acid for growing and adult 
dogs. Ornithine also possesses strong secretagogue activity for human 
GH that can be higher and more sustained than that induced by arginine 
(2). 
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SECTION I. ORAL CLONIDINE AS A SECRETAGOGUE OF GROWTH HORMONE IN YOUNG 
AND OLD DOGS 
Introduction 
The objective of this study was to evaluate, in dogs, the 
effectiveness of various oral agents that could be mixed with the daily 
ration of food in promoting GH secretion so that later studies could 
assess effects on thymic morphology and function and immune function. 
Various agents were evaluated and the accuracy of the radioimmunoassay 
(RIA) procedures for measuring GH concentrations in plasma was 
established. 
The efficacy of oral clonidine as a secretagogue for GH in humans 
is well established. A second objective of this experiment has to 
define a dose of oral clonidine as a dietary supplement that will 
reliably induce GH secretion in young and old dogs. 
Materials and Methods 
Experiment l.:. Animals and Experimental Design 
Five 16-18 month old (young dogs) and five 6-8 year old (old dogs) 
female beagles of known age and medical background were used in this 
study. 
Each of the following dietary supplements were evaluated in both 
young and old dogs: arginine at 0.5%, 1.0% and 1.5% of the total diet 
and arginine plus ornithine, each at 1.5% of the total diet. The 
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effects of food alone on GH secretion was also evaluated i'n both young 
and old dogs. The food used in this experiment was Purina Hi Pro 
(Ralston Purina, St. Louis, MO). Each dog was fed one cup of food at 
approximately 8:30 AM and 4:30 PM. This provided each dog with between 
60 and 80 calories/kg of body weight. The dietary supplements were 
mixed with a small amount of water and allowed to soak into the food 
prior to feeding. Once on different days, arginine (25 mg/kg and 100 
mg/kg) and arginine plus ornithine (25 mg/kg each) were given 
intravenously to each of the young and old dogs. On different days 
bovine growth hormone releasing hormone (bGHRH) (1 ug/kg) and clonidine 
(16.5 ug/kg) were given intravenously to all of the dogs in the study. 
There was a minimum of 48 hours between each of the challenge stimuli. 
Venous blood samples were collected into EDTA starting between 
8:30 and 9:30 AM irranediately prior to (time zero) and at 15, 30 and 60 
minutes after each of the challenge stimuli. Blood samples were 
i111Tiediately put into crushed ice. The plasma was separated by 
centrifugation at 4°c and stored frozen at -7ooc. 
Growth hormone was determined using a canine validated RIA 
procedure developed by Dr. A. R. Parlow, Harbor UCLA Medical Center, 
Torrance, CA. Twenty micrograms of lyophilized canine GH was 
solubilized in O.OlM NaHC03 at lOOug/ml of buffer. A cold standard was 
prepared by further diluting this solution with 1% BSA-phosphate 
.buffered saline (PBS) to 10 ug/ml. The GH was iodinated to low 
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specific activity using Iodo-Beads (Pierce Chemical Company, Rockford, 
IL). The stock solution of 1:100 monkey anti-canine GH gamma globulin 
was diluted with sterile distilled water to a final concentration of 
1:31,250. Nine hundred microliters of 0.05M PBS, 100 ul of cold 
standard or unknown sample, 100 ul of iodinated canine GH and 100 ul of 
diluted monkey anti-canine GH gamma globulin were mixed together and 
incubated in tubes for lB-24 hours at room temperature. One-hundred 
microliters of goat anti-monkey garrma globulin diluted 1:12 with 
sterile distilled water, 100 ul of normal monkey serum reconstituted to 
2 ml with sterile distilled water and diluted 1:40 with 0.05 M PBS 
(both from Antibodies Inc., Davis, CA) and 2 ml of polyethylene glycol 
were added to each sample. The tubes were incubated for one hour at 
room temperature and centrifuged at 1500 x g at 4° c. The supernatant 
was removed and the pellet counted using a gamma counter. 
Values for the young and old dogs for each blood collection period 
were, within each group, analyzed and compared with the time zero 
values (least significant difference). 
Experiment 11.:. Animals and Experimental Design 
Five 20-24 month old (young dogs) and four 6.5-8.5 year old female 
beagles (old dogs} of known age and medical background were used in 
this study. 
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The young and old groups of dogs were, on different days, each 
given 16.5 ug/kg, 50 ug/kg, 150 ug/kg and 450 ug/kg of clonidine mixed 
with their normal food ration as described above. Venous blood samples 
were collected into EDTA immediately prior to (time zero) and at 30, 
·60, 90 and 120 minutes after feeding. The dogs were fed twice each 
day. The morning feedings were always between 8:30 AM and 9:30 AM 
while the afternoon feedings were always between 4:30 PM and 5:30 PM. 
Blood samples were handled in the identical fashion as described in 
experiment I. Growth hormone was determined using the same RIA 
procedure as in experiment I. 
Values for the young and old dogs were, for each collection 
period, averaged and compared with the time zero values (least 
significant difference). 
Results 
Experiment l 
Food alone, oral arginine, oral arginine and ornithine, 
intravenous arginine, and intravenous arginine and ornithine in the 
concentrations of each that were tested failed to induce any 
significant release of GH in either the young or old dogs (Table 1). 
Intravenous bGHRH (1 ug/kg) induced significant (P<0.05) GH 
release at 15 minutes (10.4 ±. 2.3 ng/ml) in the young dogs and at 15 
minutes (5.2 ±. 1.7 ng/ml) and 30 minutes (4.3 ±. 1.0 ng/ml) in the old 
dogs (Table 2). 
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Intravenous clonidine (16.5 ug/kg) induced significant (P<0.05) 
GH release at 15 minutes (47.8 + 13.4 ng/ml) and 30 minutes (24.5 + 9.5 . - -
ng/ml) in the young dogs and at 15 minutes (13.0 ±_ 7.9 ng/ml) in the 
old dogs (Table 3). 
Experiment ll 
The food ration supplemented with clonidine at 16.5 ug/kg produced 
significant (P<0.05) GH secretion in young dogs (13.6 ±_ 8.1 ng/ml). 
No significant amounts of growth hormone were secreted in response to 
clonidine at this dose in the old dogs (Figures 1, 2). 
When the food ration was supplemented with clonidine at 50.0 ug/kg 
significant plasma (P<0.05) elevation of GH occurred in young dogs at 
30 minutes (24.3 ±_ 12.0 ng/ml) and at 30 minutes (12.3 + 4.3 ng/ml) and 
60 minutes (13.0 ±_·2.5 ng/ml) in the old dogs (Figures 1, 2). 
Clonidine supplemented at 150 ug/kg in the normal food ration 
produced significant (P<0.05) GH secretion at 30 minutes in young 
(30.5 ±_ 8.0 ng/ml) and old (31.1 ±_ 9.3 ng/ml) dogs (Figures 1, 2). 
With clonidine supplementing the daily food ration at 450 ug/kg 
significant ( P< O. 05) GH secretion occurred at 30 minutes in the young 
dogs (31.5 + 12.1 ng/ml) and at 30 minutes (41.0 ±_ 13.5 ng/ml) and 60 
minutes (25.5 + 8.4 ng/ml) in the old dogs (Figures 1, 2). 
Clonidine supplementation at 16.5 ug/kg and 50.0 ug/kg had no 
clinically detectable side effects in either the young or old dogs. 
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Mild sedation and slightly pale oral mucous membranes were observed at 
the 150 ug/kg dose of clonidine. With the 450 ug/kg dose of clonidine 
marked sedation and very pale oral mucous membranes were noted. 
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Tab 1 e 1 
Growth Hormone Release in Response to Various Agents 
Agent Dose Route GH Release 
Food Oral 
Arginine 0.5% Oral 
Arginine 1.0% Oral 
Arginine 1.5% Oral 
Arginine 25 mg/kg IV 
GHRH 1 ug/kg IV + 
Clonidine 16.5 ug/kg IV + 
Arginine & Ornithine 1. 5% each Oral 
Arginine & Ornithine 25 mg/kg each IV 
Arginine 100 mg/kg IV 
+ = Significant (P<0.05) GH release 
- - Failure to release GH 
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Table 2 
Growth Hormone Release in Response to Intravenous bGHRH (1 ug/kg) 
Number 
of 
Samples 
y;oa 
5/5 
5/5 
5/5 
5/5 
Time Post 
Treatment 
(minutes) 
0 
15 
30 
60 
a Y = Young; 0 = Old 
* P<0.05 
Young 
(Mean + SEM) 
GH (ng/ml) 
2.4 + 0.2 
10.4*+ 2.3 
4.2 + 0.8 
2.4 + 0.2 
Table 3 
Old 
(Mean GH + SEM) 
GH (ng/iiil) 
2.2 + 0.2 
5 .2*+ 1. 7 
4.3*+ 1.0 
2.3 + 0.3 
Growth Hormone Release in Response to Intravenous 
Clonidine (16.5 ug/kg) 
Number 
of 
Samples 
y;oa 
5/5 
5/5 
5/5 
5/5 
Time Post 
Treatment 
(minutes) 
0 
15 
30 
60 
a Y = Young; O = Old 
* P<0.05 
Young 
(Mean + SEM) 
GH (ng/ml) 
2.9 + 0.3 
47.8*+ 13.4 
24.5*+ 9.5 
5.6 + 1.9 
Old 
(Mean GH + SEM) 
GH (ng/ml) 
2.2 + 0.2 
13.0*+ 7. 9 
5.4*+ 3.3 
4.4 + 1.3 
Figure 1. Growth Hormone Secretion in Young Dogs in Response to Oral 
Clonidine Supplementation of the Daily Ration of Dry Food 
Figure 2. Growth Hormone Secretion in Old Dogs in Response to Oral 
Clonidine Supplementation the Daily Ration of Dog Food 
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Discussion 
Food alone did not stimulate GH secretion in the dogs tested. 
This is important since excitement (stress) is a factor known to 
stimulate GH secretion in some species (23). Judged subjectively by 
the author, the dogs in this study were always very excited by food 
preparation and feeding. 
Arginine and arginine combined with ornithine failed to induce GH 
secretion in any of the dogs. The failure of arginine and ornithine to 
induce GH secretion in the dogs tested is consistent with some of the 
prior observations in dogs (20). This was disappointing since arginine 
is known to be a potent secretagogue for GH in humans and rodents 
(2,20). Likewise, ornithine possesses strong secretagogue activity for 
human pituitary GH (2,20). Differences in species response to various 
GH secretagogues apparently do exist. The mechanism of arginine GH 
secretagogue activity is unknown but possibly involves insulin-induced 
hypoglycemia (2). Intravenous, oral or intraduodenal arginine will 
induce a marked insulin release in humans (2). Hyperinsulinemia can 
cause hypoglycemia and insulin-induced hypoglycemia is a factor known 
to stimulate GH release in young and adolescent humans (23). Insulin-
induced hypoglycemic stimulation of GH secretion in dogs is 
inconsistent with some investigators reporting significant elevations 
and others reporting minimal responses (10,20). Interestingly, 
ornithine does not share the insulin secretagogue activity of arginine 
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and its mechanism of action on GH secretion, although unknown, may be 
different from arginine (2). 
Growth hormone releasing hormone is a known secretagogue of GH in 
the dog (20). Species differences among the GHRHs are believed to 
exist and the sequencing and full characterization of canine GHRH has 
not yet been completed (20). Apparently bGHRH is similar enough to 
canine GHRH to induce pituitary GH secretion in the dogs tested. 
Intravenous clonidine is also a known secretagogue for GH in dogs 
(26). Oral clonidine has not been established as an effective 
secretagogue of GH in dogs although oral clonidine is known to induce 
GH secretion in humans (20,27). The known GH secretagogue activity of 
bGHRH and intravenous clonidine established these agents as the 
positive controls among the other stimuli tested. The RIA procedure 
used was concluded to be a reliable method of measuring canine GH 
concentration in plasma. 
Clonidine, given orally by mixing it with dog food was determined 
to be a reliable secretagogue for GH at all doses tested in young dogs 
and in all doses except the 16.5 ug/kg dose in the old dogs. When 
given the lowest two doses of oral clonidine, GH secretion by the old 
dogs was poor when compared with the young dogs. However, at the 
highest two doses of oral clonidine given, GH secretion by the old dogs 
exceeded that observed in the young dogs. This observation is very 
significant in that it establishes that given an adequate stimulus 
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(higher clonidine dose in this case), GH secretion by dogs is not 
limited by, and may even be enhanced by, increased age. 
Although the animals were not instrumented for definitive 
measurements of blood pressure, the pale oral mucous membranes observed 
when the highest two doses were given probably indicated hypotension. 
From the concentrations of GH produced by the various doses and the . 
observed side effects of clonidine, it is estimated that the optimum 
oral dose of clonidine needed to achieve safe and reliable GH secretion 
is 100 ug/kg. 
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SECTION II. ORAL CLONIOINE AS A THYMOTROPHIC AGENT IN MIDDLE AGED DOGS 
Introduction 
The morphologic restoration of the thymus glands of normal adult 
dogs and immunodeficient dwarf Weimaraner dogs in response to 
,exogenously administered bGH has previously been established by Roth et 
al. (49) and Monroe et al. (42). The improvement of canine thymus 
endocrine function in response to exogenously administered bGH was 
established recently by Goff and others (24). Goff et al. demonstrated 
that bGH would consistently restore the age associated decline of 
plasma thymulin concentrations in middle age (33-55 months) and old 
(63-83 months) beagle dogs when compared with dogs given BSA (24). 
Morphologic features of a young (prior to age associated involution) 
thymus gland were restored in the middle age but not the old dogs who 
were given bGH (24). 
The experiments described in the previous sections established a 
dose (100 ug/kg) of oral clonidine that can be mixed with the daily 
food ration that will safely and reliably induce GH secretion of either 
young or old dogs. It is now possible to test the hypothesis that 
clonidine, mixed with the food ration of dogs on a daily basis will 
induce endogenous GH secretion that will in turn restore thymus gland 
morphology and function and the thymus-dependent immune system. Immune 
system restoration may ultimately decrease the incidence of diseases 
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associated with aging and immune senescence. 
Materials and Methods 
Animals and Experimental Design 
Twelve four-year-old female beagle dogs of known medical history 
were used in this part of the study. 
The twelve dogs were segregated into two groups of six individuals 
that approximated each other by the additional characteristic of 
weight. One group (experimental) had their daily food ration 
supplemented with 100 ug/kg of clonidine for 30 days. The other group 
(control) had their daily food ration supplemented with distilled water 
(1 ml/kg of body weight) for 30 days. All dogs were fed twice a day, 
once between 8:30 AM and 9:30 AM and again between 4:30 PM and 5:30 PM. 
Venous blood samples were collected into EDTA on the first (day 1) 
and last (day 30) days of the feeding trial prior to feeding, and at 
30, 60 and 90 minutes after feeding for evaluation of plasma GH 
concentrations. Plasma GH concentrations were measured with the same 
HIA procedure as was used in section I of this thesis. 
Venous blood was also collected from each dog into acid citrate 
dextrose (ACD) once each week (beginning one week before the start of 
the experiment) following the morning meal to assess lymphocyte 
responsiveness to standard mitogens (concanavalin-A, pokeweed mitogen, 
phytohemagglutinin) by a method previously reported (49). The weekly 
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values for each group were compared and expressed as percent of control 
values. Percent of control values were calculated by averaging the 
percents of the average control values for each experimental dog. 
On the last day of the feeding trial and after the morning meal 
was consumed, venous blood was drawn into EDTA for determination of 
plasma thymulin titers. Plasma thymulin titers were determined in the 
laboratory of Dr. Genevieve Incefy, Memorial Sloan-Kettering Cancer 
Center, New York, NY. The plasma thymulin assay is based upon rosette 
inhibition of mouse spleen cells incubated for 75 minutes at 37° C with 
azathioprine. Rosette forming cells from spleens of thymectomized mice 
are less sensitive to azothioprine than are cells from normal mice. 
Plasma with thymulin activity restores to normal the sensitivity to 
azathioprine of rosette-forming cells from adult thymectomized mice 
resulting in inhibition of rosette formation (24,28). Data were 
converted to the log2 of the reciprocal of the titer for comparison. 
One week after the start of the feeding trial, each dog was 
immunized with heat-killed strain 19 of Brucella abortus. Antibody 
responses were determined with a standard tube agglutination test on 
serum collected prior to immunization on day 1 and again on day 30. 
On day 30 each dog had an intravenous glucose tolerance test 
performed using 500 mg/kg of glucose. Venous blood samples were 
collected prior to glucose administration, and at 5, 10 15, 25, 35, 45 
and 60 minutes after glucose administration. Glucose values were 
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determined on an automated system (Rotachem IIa, American Instrument 
Company, Silver Spring, MD). 
Approximately one week after the conclusion of the feeding trial, 
each dog was euthanatized using an intravenous injection of a 
barbiturate substance (Sleepaway, Fort Dodge Laboratories, Inc., Fort 
Dodge, IA). Each dog was necropsied within 5 minutes of death. Thymus 
tissue and samples of other major organs were collected from each dog 
and fixed in 10% formalin. 
Results 
Significant (P< 0.01) amounts of GH were secreted by the 
experimental group at 30, 60 and 90 minutes on day 1 when compared with 
controls (Figure 3). There was no significant difference between the 
experimental and control group in the amount of GH secreted on day 30 
(Figure 3). Significantly more GH was secreted by the experimental 
group on day 1 at 30 minutes (P<0.05), 60 minutes (P = 0.07) and 90 
minutes (P<0.01) than at the corresponding times on day 30 (Figure 3). 
The average mitogen responsiveness was significantly (P<0.05) 
higher in the experimental group when compared.with controls. The 
results of the blastogenic response to the mitogens used are summarized 
in Table 4. However, blastogenic resonses were highly variable. 
Phytohemagglutinin enhanced blastogenic responses during the two weeks 
following the start of the experiment but enhancement diminished during 
the third and fourth week (Figure 4). Blastogenic responses to 
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concanavalin-A and pokeweed mitogen were enhanced during the first and 
third weeks of the experiment but diminished during the second and 
fourth week (Figures 5, 6). 
No significant difference was detected between the plasma thymulin 
titers of the experimental and control dogs on day 30 of the study 
(Figure 7). Concurrent with the determination of plasma thymulin 
titers from the dogs of this study, plasma thymulin titers were 
determined on three four-month-old pups to serve as positive controls 
for the assay (young pups have higher titers than adults). 
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Figure 3. Growth hormone secretion in middle age dogs in response to 
clonidine supplemented dog food for 30 days 
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Table 4 
Lymphocyte Blastogenesis in the Clonidine and Control Fed Dogs During 
the Four Week Treatment Period 
Mi to gen 
None 
PHA SI 
PHA dcpm 
Con A SI 
Con A dcpm 
PWM SI 
PWM dcpm 
Clonidinea 
382 + 82 
129.3 + 22.3b 
41,810 ! 8,190 
129.5 + 21.4b 
41,530 ! 8,030 
75.9 + 13.0 b 
25,029 ! 5,410 
Controls a 
495 + 134 
64.8 + 9.3 
25,120 ! 5,420 
74.2 + 10.9 
28, 590 ! 5, 710 
41.0 + 5.5 
15,390 ! 3,240 
a Each value represents the mean (+ SEM) of four weekly 
determinations on six animals per group-during the clonidine feeding 
period. 
b P< O. 05 when compared to the value for control animals. 
300 -
_J 250 -
0 
0::: 
f-
200 z -
0 
u 
LL 150 0 -
f-z 
w 100 u -
0::: 
w 
0... 50 -
0 ' 
-1 
37 
LYMPHOCYTE BLASTOGENESIS 
PHA dcpm 
. 
. 
. 
' ' ' ' 
0 1 2 3 
TIME (WEEKS) 
' ' 
4 
Figure 4. Blastogenic responses of lymphocytes to phytohemagglutinin 
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Figure 5. Blastogenic responses of lymphocytes to concanavalin-A 
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Figure 6. Blastogenic responses of lymphocytes to pokeweed mitogen 
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PLASMA THYMULIN TITERS ON DAY 30 
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Figure 7. Plasma thymulin titers of three normal pups (four-months-old), 
experimental dogs fed clonidine, and control dogs on day 30 of 
the feeding trial 
Figure 8. Histologic sections of thymus glands of dogs fed a distilled 
water supplemented diet in Figures b and c have greater 
cellularity and less adipose tissue than in Figures a, d, e, 
and f, 17.6X 

Figure g. Histologic sections of thymus glands of dogs fed a clonidine 
supplemented diet in Figures a, d, e, and f have greater 
cellularity and less adipose tissue than in Figures b and c, 
17.6X 
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The morphologic data were assembled from the unbiased observation 
of a pathologist who was unaware of which treatment group each dog had 
been assigned to. The thymus morphology was judged to be normal (age 
related involution) in four of the six control animals (Figures 8 a, d, 
e, f). Surprisingly, two control dogs had better developed thymus 
tissue than expected for dogs of this age (Figures 8 b, c). Four of 
six experimental dogs had improvement in their thymus morphology 
(Figures 9 a, d, e, f). Two of six experimental dogs had appropriate 
age associated thymic involution (Figures 9 b, c). 
There were no significant differences between the experimental and 
control groups in their antibody response to Brucella abortus 
immunization (data not shown). 
Glucose tolerance tests in all dogs done at the end of the 
experiment were normal {data not shown). 
Discussion 
The excellent secretagogue activity of oral clonidine (100 ug/kg 
mixed with food) for GH was clearly apparent on day 1 but absent on day 
30. This may have occurred because of the phenomenon of tolerance, 
also known as tachyphylaxis, desensitization and down regulation. Down 
regulation is recognized in many clinical situations. Down regulation 
simply means that with chronic administration of a drug it takes larger 
doses to produce effects that are apparent at lower doses in naive 
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subjects (52). For example, human asthmatics have a decreased 
responsiveness to epiniphrine after multiple administrations (52). 
Both metabolic and receptor changes are involved in the altered 
sensitivity of some drugs. Metabolic tolerance to alcohol and 
barbiturates in.humans and barbiturates in dogs are derived, in part, 
from increased metabolism of these substances with chronic use (20,51). 
Circulating antibody to insulin receptors is a known cause of insulin 
resistance in diabetic humans and is a suspected cause of insulin 
resistance in diabetic dogs (20). 
Other possible mechanisms to explain down regulation involve 
changes in the drug receptors themselves (52). A reduction in the 
number of receptors or a proliferation of "inactive" receptors have 
also been cited as explanations for down regulation (52). Certain 
models propose that biochemical changes other than the drug receptors 
are responsible for down regulation through mechanism like second-
messenger (cyclic AMP/adenyl cyclase) modulation (52). 
It is unknown by what mechanism or how quickly these beagle dogs 
become tolerant to the secretagogue effects of clonidine. All that can 
be concluded is that down regulation to oral clonidine occurs in dogs 
within 30 days when administered twice each day at a dosage of 100 
ug/kg with food. 
The responses to standard mitogens were highly variable. When the 
data from each week were averaged together the experimental group had 
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significantly (P<0.05) greater response to the mitogens tested than 
did the control group. The reasons for high variability of the 
responses to standard mitogens are not fully understood but they have 
been observed previously (42,49). The data do suggest that oral 
clonidine can, at least transiently, enhance immune function as 
determined by lymphocyte responses to mitogens. Whether this enhanced 
immune function is the result of the GH secretion induced by clonidine 
before the dogs stopped responding to it or via another mechanism is 
unknown. 
Plasma thymulin titers in the dogs of the experimental and control 
groups were comparable on day 30. It is unknown if clonidine had any 
beneficial effect on thymic endocrine function as determined by a rise 
in plasma thymulin titers prior to day 30. From the experiments of 
Goff et al. (24) who were able to consistently induce a rise in plasma 
thymulin titers in beagle dogs given exogenous GH, it would be expected 
that had the dog not become unresponsive to oral clonidine, a rise in 
plasma thymulin titers should have followed the endogenous GH secretion 
induced by clonidine. Since tolerance to clonidine apparently occured 
and since plasma thymulin titers were not determined at frequent 
intervals, t~e true relationship between oral clonidine, growth hormone 
and plasma thymulin titers remains speculative. 
Antibody response to challenge with.!!..:_ abortus reflect primarily 
B-lymphocyte function rather than T-lymphocyte function although some 
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subsets of T-lymphocytes modulate the activity of B lymphocytes. The 
antibody responses in both groups of dogs to .!!.:_ abortus were comparable 
and do not directly reveal any measure of irrrnune function enhancement 
following clonidine administration. 
Since the plasma thymulin titers and .!!.:_ abortus antibody titers 
were comparable to control values and lymphocyte responses to mitogens 
were so variable it is unlikely that clonidine, as given, has any 
clinically relevent benefit to immune function. 
The morphology of the thymus glands was judged to be normal 
(appropriately involuted for four year old dogs) in four of the six 
control dogs. The finding of two of six dogs with better than 
anticipated thymus morphology was unexpected. However, many authors 
have recorded the persistence of epithelial cells after thymic atrophy 
in rodents and regional differences in cell proliferation within the 
thymus are recognized in other species (33). The relationship between 
the numbers of thymocytes and epithelial cell nuclei is not age related 
and, in some individuals, differ in different parts of the same gland 
(33). The size of the adult human thymus gland is very variable and 
even in glands much reduced in size, there are often compact aggregates 
of thymocytes bulging into the adipose tissue around the medulla (33}. 
Based upon these observations in other species, it is possible that the 
natural variability of adult thymus tissue could account for the 
observed differences in thymic morphology of the control group. 
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The morphology of the thymus (increased cellularity of the cortex, 
decreased width of the interlobular septae and decreased amounts of 
adipose tissue) was judged to be enhanced in four of the six dogs in 
the experimental group. Since none of these dogs had gross differences 
in their thymus glands and enhancement was judged upon microscopic 
appearance, it is possible that natural variability of adult. thymus 
tissue accounted for the increased cellularity of the thymic morphology 
noted. Although four of six experimental dogs showed improved 
microscopic appearance, the sample sizes in this study were too small 
to conclude that thymuses from the experimental dogs benefited by 
increased cellularity from clonidine. The possibility that the 
observations of improved thymic morphology reflect natural variability 
cannot be dismissed. 
There was no clinically apparent effect on glucose metabolism in 
the experimental group when compared with controls. All dogs had 
normal intravenous glucose tolerance tests on day 30. Growth hormone 
excess is known to produce glucose antagonism and a depressed glucose 
tolerance test (prolonged hyperglycemia) (l,20). Since tolerance to 
clonidine developed, growth hormone was not being secreted in 
significant amounts on day 30 when the glucose tolerance tests were 
conducted. Had glucose tolerance tests been conducted more frequently, 
effects of clonidine induced GH secretion on glucose metabolism may 
have been noted. 
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SUMMARY AND CONCLUSIONS 
This study was conducted in the hope of identifying a non-toxic 
oral substance that could be given to dogs mixed with their food with 
the ultimate hope of decreasing the incidence of age-related diseases 
that are linked to immune senescence. Based upon previous 
investigations in dogs by Roth et al. (48,49), Monroe et al. (40,42) 
and Goff et al. (24) an attempt to reverse the age associated decline 
of immune competence was made by evaluating several secretagogues of 
GH. Arginine and ornithine although effective secretagogues of GH in 
some species were shown here to be ineffective in beagle dogs. 
Oral clonidine (100 ug/kg), when mixed with dog food was found to 
be a safe and reliable secretagogue of GH. Old dogs were found to be 
capable of GH secretion in response to oral clonidine that exceeded 
that of young dogs. This established that, in beagle dogs at least, GH 
secretion is not obtunded by, and may be enhanced by, advanced age if 
the proper stimulus is provided. However, the release of GH by oral 
clonidine is diminished with daily administration. Humans who 
chronically take clonidine for control of essential hypertension are 
not reported to suffer from an increased risk of diabetes mellitus or 
acromegaly. Although the total adult human dose (0.2 to 0.8 mg/day 
given in divided doses) is far less than that given to the dogs in this 
study, humans might also experience down regulation with respect to GH 
secretion or there would likely be a higher incidence of side effects 
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referable to GH excess. It is not known how soon down regulation to 
oral clonidine develops in dogs but it apparently does occur within 30 
days. 
Likewise, immune enhancement seems to be blunted by the daily 
administration of clonidine. The apparent transient beneficial effects 
of phytohemagglutinin on lymphocyte blastogenesis is, however, 
encouraging. 
Thymus endocrine function (as reflected by plasma thymulin titers) 
was not enhanced by the addition of clonidine to dogs diets. 
Insufficient evidence exists in this study to conclude that there was 
any benefit on thymus morphology from feeding clonidine supplemented 
food to dogs. The natural variability of adult thymus glands and the 
induction of tolerance to clonidine precluded a clear outcome from this 
study. 
Future investigations giving clonidine less frequently might avoid 
the induction of down regulation and clear benefits of clonidine 
supplemented food might become evident. 
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APPENDIX: INFORMATION ON THE USE OF ANIMALS IN RESEARCH 
This research was conducted according to the rules and regulations 
of the Animal Welfare Act. 
